The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...

Vor Biopharma shares fell sharply Tuesday in premarket trading after the company priced its $100 million offering below recent trading prices. Shares traded 31% lower ahead of the morning bell at ...

Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million. In ...

Vor Biopharma (NASDAQ:VOR) trading was halted on September 18, 2025, pending any announcements from the company. The stock fell over 16% this week. Separately, 10% owner Reprogrammed Interchange and ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from Vor ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Vor Biopharma (NASDAQ:VOR) stock is up 116% in the last year, providing strong gains for shareholders.

VOR Biopharma's valuation surged after in-licensing telitacicept and securing PIPE financing, but capital structure uncertainty persists. Telitacicept's positive phase 3 data in Sjögren's disease ...

Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.

We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive ...

Captain Vor is an iconic villain in Warframe and the first boss you’ll encounter in the game. Before the Isleweaver update, there were only two variants of Vor in the game: Captain Vor and Corrupted ...

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

(RTTNews) - Vor Bio (VOR) and RemeGen Co. announced entry into a license agreement granting Vor Bio global rights excluding China, Hong Kong, Macau and Taiwan to develop and commercialize telitacicept ...